Literature DB >> 11255382

Linezolid and reversible myelosuppression.

S L Green, J C Maddox, E D Huttenbach.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11255382     DOI： 10.1001/jama.285.10.1291

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  28 in total

Review 1.  Linezolid-induced thrombocytopenia in impaired renal function: is it time for a dose adjustment? A case report and review of literature.

Authors:  A P Cossu; M Musu; P Mura; L M De Giudici; G Finco
Journal:  Eur J Clin Pharmacol       Date:  2014-01       Impact factor: 2.953

2.  Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.

Authors:  N Duewelhenke; O Krut; P Eysel
Journal:  Antimicrob Agents Chemother       Date:  2006-11-06       Impact factor: 5.191

3.  In vivo efficacy of a novel oxazolidinone compound in two mouse models of infection.

Authors:  Charles J Gill; George K Abruzzo; Amy M Flattery; Andrew S Misura; Ken Bartizal; Emily J Hickey
Journal:  Antimicrob Agents Chemother       Date:  2007-07-02       Impact factor: 5.191

4.  Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation.

Authors:  Shankar S Iyer; Qiong He; John R Janczy; Suzanne L Cassel; Fayyaz S Sutterwala; Eric I Elliott; Zhenyu Zhong; Alicia K Olivier; Jeffrey J Sadler; Vickie Knepper-Adrian; Renzhi Han; Liang Qiao; Stephanie C Eisenbarth; William M Nauseef
Journal:  Immunity       Date:  2013-08-15       Impact factor: 31.745

5.  In vitro susceptibility of Coxiella burnetii to linezolid in comparison with its susceptibilities to quinolones, doxycycline, and clarithromycin.

Authors:  A Gikas; I Spyridaki; E Scoulica; A Psaroulaki; Y Tselentis
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

6.  In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.

Authors:  Peter J Petersen; Patricia A Bradford; William J Weiss; Timothy M Murphy; P E Sum; Steven J Projan
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

7.  Hematologic effects of linezolid: summary of clinical experience.

Authors:  Stanton L Gerson; Sheldon L Kaplan; Jon B Bruss; Vu Le; Felix M Arellano; Barry Hafkin; David J Kuter
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Comparative study of the effects of pyridoxine, rifampin, and renal function on hematological adverse events induced by linezolid.

Authors:  Alex Soriano; Mar Ortega; Sebastián García; Georgina Peñarroja; Albert Bové; Miguel Marcos; Juan C Martínez; José A Martínez; Josep Mensa
Journal:  Antimicrob Agents Chemother       Date:  2007-04-30       Impact factor: 5.191

Review 9.  Newer treatment options for skin and soft tissue infections.

Authors:  Murugan Raghavan; Peter K Linden
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Probable linezolid-induced pancytopenia.

Authors:  Nita Lakhani; William Thompson; Anne Marie Bombassaro
Journal:  Can J Infect Dis Med Microbiol       Date:  2005-09       Impact factor: 2.471
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.